TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06622759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTG
Description: Connective Tissue Graft has been widely used around implants to increase either the thickness of the soft tissues or the width of keratinized tissues. It is considered the gold standard for soft tissue grafting. The main drawbacks are the donor morbidity and the limit amount of intraoral donor sites. In this study it will be used in the test 1 group in order to compare its clinical results with the other groups.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen Matrix
Description: Collagen matrix has been used in several studies in order to evaluate its clinical properties over the last years. In this study, the graft will be placed buccally at the time of implant placement in the aesthetic zone in order to assess its clinical and radiographic properties in terms of buccal bone resorption and soft tissue augmentation. Histological assessment and Patient Reported outcomes will also be evaluated.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control group
Description: In the control group, the implant will be placed without any kind of soft tissue graft in order to compare this treatment modality that many clinicians apply at the clinical practice.
Study: NCT06622837

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant overdenture
Description: With the assistance of these stereolithographic surgical guides and submerged surgical technique, 4 dental implants (IS III Active Implant, Neo BioTech) were placed in the canines and premolars regions of the maxillary arch, and 2 dental implants were placed in the canines region of the mandibular arch.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant overdenture
Description: With the assistance of these stereolithographic surgical guides and submerged surgical technique, 4 dental implants (IS III Active Implant, Neo BioTech) were placed in the canines and premolars regions of the maxillary arch, and 2 dental implants were placed in the canines region of the mandibular arch.
Study: NCT06622057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D07001-Softgel Capsules
Description: D07001-softgel capsule is an oral gemcitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D07001-Softgel Capsules
Description: D07001-softgel capsule is an oral gemcitabine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo has the same excipient with D07001-softgel but without active pharmaceutical ingredients (APIs)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine, a fluoropyrimidine carbamate derivative, is an oral tumor activator and selective cytotoxic agent.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine, a fluoropyrimidine carbamate derivative, is an oral tumor activator and selective cytotoxic agent.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine, a fluoropyrimidine carbamate derivative, is an oral tumor activator and selective cytotoxic agent.
Study: NCT06621901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Description: Individuals will be placed on a high protein diet for 10 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Protein Diet
Description: Individuals will be placed on a normal protein diet for 10 days.
Study: NCT06622174

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pulse radiotherapy
Description: Pulsed radiotherapy combined with PD(L)-1 inhibitors targeting 2 to 5 progressive extracranial lesions per cycle
Study: NCT06624280

Intervention type: PROCEDURE
Intervention: single-event multilevel surgery
Description: surgical orthopedic approach where multiple deformities are corrected in one solution, often involving both lower limbs, to improve walking performance
Study: NCT06619327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilient Together for Dementia
Description: RT-D has been developed based on feedback from couples and dementia clinicians as well as prior successful dyadic interventions. RT-D was developed based on the Recovering Together (RT) dyadic intervention for acute neurological illnesses and is being adapted to address the needs of couples navigating new dementia diagnoses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEUC
Description: The MEUC condition was also developed based on the comparison trial in the Recovering Together dyadic intervention, and was adapted based on feedback from prior studies. The program is self-guided and provides educational information similar to the RT-D condition, but with no skills practice or weekly sessions with a therapist.
Study: NCT06623825

Intervention type: DEVICE
Intervention: teleconsultation by Augmented Reality smart glasses
Description: The device operated on Android 9.0 and it connected to 5G connection with a bandwidth speed 30-mbps delivering a very low latency. The device supported real time screen sharing and therefore the data were collected from smart glasses including visual and audio with real-time two-way communications. Physicians at the hospital can access the information and video via a mobile app, enabling continuous monitoring of patients. The features facilitate healthcare providers at SRRSH and medical personnel in the HAG2022 polyclinic to discuss the patient's condition, exchange, and deliberate on the pre-hospital medical examinations of the patient.

Intervention type: DEVICE
Intervention: teleconsultation by two-way radio connection.
Description: adhering to the standard conventional triage process without the AR tool, only using a two-way radio connection.
Study: NCT06623513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib Sodium
Description: Parecoxib Sodium 40 mg administered intravenously 30 minutes before the ERCP procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin suppository
Description: Indomethacin suppository 100 mg administered rectally 30 minutes before the ERCP procedure.
Study: NCT06619977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analgesia nociception monitoring (ANI)
Description: Analgesia nociception index (ANI; MetroDoloris Medical Systems, Lille, France) is a noninvasive tool for monitoring the intraoperative state of the autonomic nervous system, in particular - the parasympathetic nervous system. The ANI algorithm uses data from one lead ECG trace. Heart rate variability, or the beat-to-beat alterations in heart rate, is a well-known and recognised noninvasive indicator of autonomic nervous system activity.
Study: NCT05132712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Potassium
Description: ACE inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: multi-vitamins
Description: placebo drug
Study: NCT04776018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: TAK-981 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezagitamab
Description: Mezagitamab SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezagitamab
Description: Mezagitamab SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezagitamab
Description: Mezagitamab SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab and Hyaluronidase-fihj
Description: Daratumumab and Hyaluronidase-fihj SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab and Hyaluronidase-fihj
Description: Daratumumab and Hyaluronidase-fihj SC injection.
Study: NCT05186636

Intervention type: OTHER
Intervention: KPI reports
Description: Quarterly

Intervention type: OTHER
Intervention: Prescriber reports
Description: Individualized prescriber reports for acute RRT initiation patterns along with targeted education to ensure that align with best evidence-based practices
Study: NCT05293873

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow-derived mononuclear cell transplantation
Description: Bm-MNC will be transplanted at baseline, and the second transplantation will be performed 6 months after the first transplantation

Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation therapy
Description: Rehabilitation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: Rehabilitation therapy
Study: NCT06382441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tele-exercise
Description: It is a prospective and pilot study of RCT. It will be a pilot to test acceptability and feasibility of a two-armed tele-exercise RCT to mitigate symptoms and improve health for breast cancer survivors. In this study, outcome assessors and data analysts will be masked from the allocation results. The pilot will recruit 24 patients and randomly assign them to an intervention group (Group A) and an active control group (Group B). All participants in both groups will continue receiving usual care from the study hospital during the study period. Additionally, those in Group A (intervention) will receive the tele-exercise (12 home-based online training sessions + 4 psychological counselling sessions), while those in Group B (active control) will receive 4 essays on exercise and health. Outcome measurements will be repeatedly performed before and after the intervention.
Study: NCT05176483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanzalintinib
Description: Zanzalintinib orally once daily (qd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanzalintinib
Description: Zanzalintinib orally once daily (qd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanzalintinib
Description: Zanzalintinib orally once daily (qd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanzalintinib
Description: Zanzalintinib orally once daily (qd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanzalintinib
Description: Zanzalintinib orally once daily (qd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanzalintinib
Description: Zanzalintinib orally once daily (qd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanzalintinib
Description: Zanzalintinib orally once daily (qd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 360 mg IV infusion once every 3 weeks (q3w)
Study: NCT05176483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg IV infusion once every 3 weeks (q3w) for maximum of four doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg IV infusion once every 3 weeks (q3w) for maximum of four doses
Study: NCT05565274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentazocine plus placebo
Description: 30mg of pentazocine and 2milliLitre of injection water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentazocine plus placebo
Description: 30mg of pentazocine and 2milliLitre of injection water
Study: NCT04937426

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluorescent-labeled Urease Inhibitor Marker to Detect Helicobacter Pylori
Description: Diagnostic laboratory test for detection of helicobacter pylori
Study: NCT06259734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transfusion Camp Rwanda education
Description: Transfusion Camp Rwanda 3 day education intervention covering all aspects of safe blood transfusion practices as per the Rwanda Biomedical Centre National Transfusion Guidelines
Study: NCT05176483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg IV infusion once every 3 weeks (q3w) for first four doses, and then 480 mg IV infusion once every 4 weeks (q4w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg IV infusion once every 3 weeks (q3w) for first four doses, and then 480 mg IV infusion once every 4 weeks (q4w)
Study: NCT04799860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health promotive work-way
Description: Clinical intervention: The patient is asked to fill in a screening form with life-style related questions. The caregiver takes adequate measures according to the recommendations of the national guideline and the filled in screeing form. The caregiver documents the measures taken.~Implementation intervention as described previously: using tailored strategies to support implementation of the gudieline-based recommendations
Study: NCT04856943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Smartconsent application
Description: Patients asigned to smartconsent group will sign informed consent through a Tablet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Patient asigned to control group will sing the informed consent in papel, as it is performed in clinical practice
Study: NCT05176483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg IV infusion once every 4 weeks (q4w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab
Description: IV administration of nivolumab + relatlimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab
Description: IV administration of nivolumab + relatlimab
Study: NCT05357144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loyalty card program at drug shops & supply of HIVST and SRH products
Description: Consenting drug shops will receive:~* training on Malkia Klabu implementation;~* HIVST training (same as comparison drug shops);~* procedures for referring to youth-friendly HIV/SRH services;~* a monthly supply of HIVST reserved for free distribution to AGYW, with free price stickers and pre-packaged with referral information; and~* reimbursement for SRH products given to AGYW (e.g., birth control pills).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparison drug shops
Description: Consenting drug shops in the comparison arm catchment areas will have access to the Maisha Meds inventory management application system for offline digital recording of HIVST, HIVST kits earmarked for free to AGYW, guidance on HIV care referral plan to facilitate linkage to nearby health facilities for AGYW. These control drug shops will not participate in Malkia Klabu (Queen Club) program implementation.
Study: NCT05189093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection
Description: There will be a total of 4 cohorts, each cohort will explore 1-2 dose levels, i.e. 10 mg/kg and 15 mg/kg, with an expected enrollment of 40-80 cases. The 10 mg/kg dose level will be enrolled first, the After discussion between the sponsor and the DSC, the 15 mg/kg dose level will be enrolled if necessary. Based on the DMC analysis, the no-trend cohort will be enrolled in a maximum of 10 cases (with the possibility of stopping enrollment halfway through).
Study: NCT04954742

Intervention type: DRUG
Group type: OTHER
Intervention: Riociguat
Description: Treatment will be initiated and individually adjusted according to systolic blood pressure and tolerability. During the titration phase, each patient will be asked to measure their peripheral systolic blood pressure and the heart rate at home three times per day and document the values in the patient diary. The results will be examined by the investigator during each visit/phone call-visit. Provided that the systolic blood pressure is ≥ 95 mmHg measured at trough before intake of each dose and the patient has no signs or symptoms of hypotension, the dose of study medication will be titrated by +0.5 mg tid every 2 weeks until maximal tolerated dosage (maximal permitted dose: of 2.5 mg tid). After the titration period, blood pressure should be measured upon signs or symptoms of hypotension. Maintenance dose: The established individual dose should be maintained unless signs and symptoms of hypotension occur.
Study: NCT04183738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs
Description: In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NRTIs
Description: In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 800mg tablet by mouth once daily for 96 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: 800mg tablet by mouth once daily for 96 weeks.
Study: NCT04743375

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wound dressing application
Description: Sericin dressing with collagen or Bactigras will be used as a primary dressing for treating the STSG donor site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wound dressing application
Description: Sericin dressing with collagen or Bactigras will be used as a primary dressing for treating the STSG donor site.
Study: NCT05238532

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CT303
Description: Once a time, intravenous injection~* CT303 Starting Dose : 1.0\*10\^6 cells/kg~* CT303 Increasing Quantity Dose : 2.0\*10\^6 cells/kg
Study: NCT05261932

Intervention type: PROCEDURE
Intervention: AI-assisted guided biopsy
Description: The surface of the adenoma was classified and identified by the AI system, and different areas of the adenoma were marked by distribution to guide the endoscopist for biopsy to obtain the poorly differentiated portion of the lesion.

Intervention type: PROCEDURE
Intervention: AI-assisted guided biopsy
Description: The surface of the adenoma was classified and identified by the AI system, and different areas of the adenoma were marked by distribution to guide the endoscopist for biopsy to obtain the poorly differentiated portion of the lesion.
Study: NCT04744181

Intervention type: DRUG
Intervention: Ferric carboxymaltose
Description: administration of a single dose of ferric carboxymaltose in those patietns who fulfill the inclusion criteria

Intervention type: DRUG
Intervention: B vitamin
Description: administration of a single dose of B vitamin in those patietns who fulfill the inclusion criteria

Intervention type: DRUG
Intervention: Folic acid
Description: administration of a single dose of folic acid in those patietns who fulfill the inclusion criteria
Study: NCT05819853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Injectable Product (Wegovy and/or Ozempic)
Description: 10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Injectable Product (Wegovy and/or Ozempic)
Description: 10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg
Study: NCT06311656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853)
Description: Administered orally fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853)
Description: Administered orally fasted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853)
Description: Administered orally fed and fasted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853)
Description: Administered orally fed and fasted.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT04931459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACU193
Description: Intravenous ACU193

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Placebo
Study: NCT04183738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100mg tablet by mouth once daily for 96 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100mg tablet by mouth once daily for 96 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: 50mg tablet by mouth once daily for 96 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: 50mg tablet by mouth once daily for 96 weeks.
Study: NCT05393271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4011499
Description: VH4011499 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4011499
Description: VH4011499 will be administered.
Study: NCT05310344

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel and bevacizumab
Description: Patients will receive albumin-bound paclitaxel (260 mg/m2) and bevacizumab (7.5mg/kg) intravenously every 21 days. The total treatment periods are no more than 6 cycles.
Study: NCT05671133

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinician Decision Support Tool
Description: Clinician Decision Support Tool that provides information about patient's statistical probability of suicide attempt in next 1 month
Study: NCT04313036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: 25 mg/kg/day at 4 divided doses of 6.25 mg/kg, 2-h infusion given for 5 days, if not in CR treatment continued for \>/= 21 days or per discretion of enrolling physician.
Study: NCT03652870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nortriptyline
Description: A medication used to treat conditions such as depression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: A medication used to treat conditions such as depression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose and magnesium stearate tablet to be used as a placebo.
Study: NCT04725617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Standard smoking cessation treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Standard smoking cessation treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: Standard smoking cessation treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: Standard smoking cessation treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Approach 1 to Reduce Smoking
Description: Behavioral health intervention option 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Approach 2 to Reduce Smoking
Description: Behavioral health intervention option 2